Granules India receives EIR from USFDA for Gagillapur facility

16 Aug 2017 Evaluate

Granules India’s Gagillapur facility located at Hyderabad, Telangana, India has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA). This facility was inspected by USFDA in October 2016 and there were no observations during the inspection. This facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).


Granules India Share Price

593.90 -12.00 (-1.98%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.